The place of elective vitrectomy in the management of patients with Candida endophthalmitis.
A general review of the treatment of Candida endophthalmitis is undertaken, with particular emphasis on the efficacy of various drugs currently in use. Their absorption by the eye when given systemically is also considered. The limitations of medical treatment for this condition are discussed and the theoretical reasons for vitrectomy considered. Six cases that underwent vitrectomy are reviewed, and the indications for vitrectomy in Candida endophthalmitis are discussed. A tentative overall plan for the management of such cases is given.
D000666:Amphotericin B / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000601:surgery*; D009877:Endophthalmitis / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D014792:Visual Acuity; D014821:Vitrectomy
D000666:Amphotericin B; D005437:Flucytosine; D007654:Ketoconazole